Mirati Therapeutics Announces Publication of Updated Clinical Data for Adagrasib By Investing.com
Mirati Therapeutics (MRTX) announces the publication of updated clinical data for adagrasib
Merati Therapeutics (NASDAQ:), Inc.® (MRTX) today Journal of Clinical Oncology Posted in speed contact data suggest Increase the doseKRAS, potent and selectiveG12C Inhibitory, well tolerated and showing meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract adenocarcinoma (BTC), and other solid tumors harboring KRASG12C leap. Quick communication Intended for publications deemed to represent urgent, timely, and overdue research that may have an immediate impact on patient care.
In addition, the results were presented last week in the April edition of American Society of Clinical Oncology (ASCO) Series Program. This post follows KRAZATI’s recent listing® (dose) In the National Center Comprehensive Network (NCCN) Central Nervous System (CNS) Cancer Guidelines for Patients Living with Previously Treated KRASG12CMutant non-small cell lung cancer (NSCLC) and central nervous system metastases.
Phase 2 data from the KRYSTAL-1 study demonstrates potential Increase the dose As monotherapy in patients with non-resectable or metastatic KRASG12CMutant solid tumors beyond neuroanaplastic lymphoma and colorectal cancer (CRC). Data presented were based on blinded, independent, centralized review confirmed (BICR) responses. This is the largest Phase 2 data set evaluating KRAS G12C mutant solid tumors other than non-small cell lung cancer and colorectal cancer.
The enrolled and treated population (n = 63) included (n = 63) 21 PDAC, 12 BTC, 9 appendicular adenocarcinomas, 4 gastric/esophageal adenocarcinomas, 3 small intestine adenocarcinomas, 5 ovarian adenocarcinomas, and 4 non-primary adenocarcinomas. known, 3 endometrial adenocarcinomas, and 1 breast adenocarcinoma. The median of previous lines of systemic therapy was two. The results showed an objective response rate (ORR) of 35% for the total group. In patients with PDAC, the ORR was 33%. For patients with BTC, the ORR was 42%. Notably, the results demonstrate that the safety profile of adagrasib is in line with previously reported data in patients with pretreated NSCLC and CRC.
These results demonstrate a meaningful improvement relative to the historically reported standard of care for PDAC and BTC. For patients previously treated for metastatic PDAC, the current standard of care (gemcitabine + nab-paclitaxel or liposomal irinotecan + 5FU/leucovorin) resulted in a lower ORR (3–16%).1-2 In the cohort of BTC patients not selected by vital signs, the ABC-06 A phase III trial investigating FOLFOX in a second-line setting reported an ORR of 5%.3
“We are pleased to see the results of this phase II study, which shows a significant improvement in the current standard of care for patients with unresectable or metastatic KRAS.G12CMutant solid tumors, including PDAC, BTC and other gastrointestinal (GI) and non-gastrointestinal tumors, for which there are few treatment options. It is particularly encouraging to see beneficial clinical activity in tumors of the pancreas and bile duct,”
“We are pleased to share this data demonstrating meaningful clinical activity in KRASG12Cmutant tumor types in addition to NSCLC and CRC, suggesting a potential pathway for regulatory approval Increase the dose in additional indications
The primary endpoint for the Phase 2 group The KRYSTAL-1 study was the objective response rate. Secondary endpoints included duration of response, progression-free survival, and overall survival and safety.
The results were shown last week April Course ASCO Plenary Series Program As a data presentation (Abstract 425082) entitled “KRYSTAL-1: activity and safety.” higher dose (MRTX849) in patients with advanced solid tumors harboring A KRASG12C Boom. The full summary of the presentation can be found here: Program Guide – ASCO Meeting Program Guide.
full Journal of Clinical Oncology The article can be found here.
Comments are closed.